Philip J. Hajduk

Molecular Biology · 1999–2011

A researcher in the Science corpus: 6 papers; trusts 5 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 19 citations into it; #4,102 of 17,773 by trust here, #3,659 by citations
• Computational Theory and Mathematics — 18 citations into it; #3,807 of 12,182 by trust here, #2,161 by citations
• Pharmacology — 6 citations into it
• Organic Chemistry — 5 citations into it; #233 of 1,495 by trust here, #206 by citations
• Spectroscopy — 5 citations into it

Whom Philip J. Hajduk trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Christopher A. Lipinski
2. Tudor I. Oprea
3. R. Macarron
4. A. Hopkins
5. Brian K. Shoichet
6. M. Hann
7. N. Grigorieff

Who trusts Philip J. Hajduk overall

1. Michael J. Wasko
2. Michelle Arkin
3. Nicolas Foloppe
4. Kendy A. Pellegrene
5. Yinyan Tang
6. Jeffry D. Madura
7. Christopher W. Murray
8. Matthew Paul Gleeson
9. Lívia Barros Salum
10. C. K. Surratt

Papers from Philip J. Hajduk's perspective

Ordered by how strongly the researchers Philip J. Hajduk trusts endorse each paper. Same corpus, a different order for every researcher.

1. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix (Science)
2. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery (Journal of chemical information and computer sciences)
3. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. (Journal of Medicinal Chemistry)
4. Functionality maps of binding sites: A multiple copy simultaneous search method
5. Discovering novel ligands for macromolecules using X-ray crystallographic screening (Nature Biotechnology)
6. An inhibitor of Bcl-2 family proteins induces regression of solid tumours (Nature)
7. Virtual exploration of the small-molecule chemical universe below 160 Daltons.
8. Drug-like properties and the causes of poor solubility and poor permeability. (Journal of pharmacological and toxicological methods)
9. Critical review of the role of HTS in drug discovery.
10. Is There a Difference between Leads and Drugs? A Historical Perspective (Journal of chemical information and computer sciences)

Their papers

• An inhibitor of Bcl-2 family proteins induces regression of solid tumours (2005) — 3,422 citations
• A decade of fragment-based drug design: strategic advances and lessons learned (2007) — 988 citations
• Fragment-based drug design: how big is too big? (2006) — 256 citations
• Drug discovery: A question of library design (2011) — 100 citations
• NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups (2000) — 192 citations
• Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. (1999)